Reckitt Benckiser Group (LON:RB)‘s stock had its “overweight” rating restated by stock analysts at Barclays in a note issued to investors on Wednesday, ThisIsMoney.Co.Uk reports.

Several other brokerages also recently issued reports on RB. Goldman Sachs Group set a GBX 6,820 ($89.12) price objective on shares of Reckitt Benckiser Group and gave the stock a “neutral” rating in a research report on Thursday, May 2nd. Jefferies Financial Group set a GBX 5,400 ($70.56) price objective on shares of Reckitt Benckiser Group and gave the stock a “sell” rating in a research report on Thursday, May 2nd. Deutsche Bank restated a “buy” rating and set a GBX 8,000 ($104.53) price objective on shares of Reckitt Benckiser Group in a research report on Wednesday, April 17th. JPMorgan Chase & Co. restated an “overweight” rating and set a GBX 9,000 ($117.60) price objective on shares of Reckitt Benckiser Group in a research report on Monday, April 15th. Finally, UBS Group restated a “neutral” rating and set a GBX 6,400 ($83.63) price objective on shares of Reckitt Benckiser Group in a research report on Wednesday, April 10th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Reckitt Benckiser Group currently has an average rating of “Hold” and an average price target of GBX 7,117.78 ($93.01).

Reckitt Benckiser Group stock opened at GBX 6,319 ($82.57) on Wednesday. Reckitt Benckiser Group has a 52 week low of GBX 5,559 ($72.64) and a 52 week high of GBX 7,174 ($93.74). The company has a debt-to-equity ratio of 80.49, a current ratio of 0.65 and a quick ratio of 0.47. The stock has a market cap of $44.73 billion and a P/E ratio of 20.73.

In other Reckitt Benckiser Group news, insider Christopher Sinclair purchased 1,076 shares of the company’s stock in a transaction dated Thursday, May 23rd. The stock was bought at an average cost of GBX 6,375 ($83.30) per share, for a total transaction of £68,595 ($89,631.52). Also, insider Adrian Nevil Hennah sold 13,701 shares of Reckitt Benckiser Group stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of GBX 6,143 ($80.27), for a total transaction of £841,652.43 ($1,099,767.97).

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.

See Also: How to Invest in Marijuana Stocks

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.